Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study
Motoshi Ichikawa, Ryujiro Suzuki, Kensuke Kataoka, Yasunobu Noda, Joe Shindoh, Syuichi Matsumoto, Yoshimasa Tanikawa, Kiyoshi Suzuki, Kenji Baba, Yuichiro Shindo, Masashi Kondo, Kazuyoshi Imaizumi, Hiroaki Kume, Yoshinori Hasegawa, Kenzo Takagi, Hiroyuki Taniguchi
20100801
2010 Sept 1
Lung Cancer
Second-line weekly paclitaxel in resistant or relapsed non-small cell lung cancer treated with docetaxel and carboplatin: A multi-center phase II study
Lung Cancer. 2010 Sept;69(3):319-322, Motoshi Ichikawa, Ryujiro Suzuki, Kensuke Kataoka, Yasunobu Noda, Joe Shindoh, Syuichi Matsumoto, Yoshimasa Tanikawa, Kiyoshi Suzuki, Kenji Baba, Yuichiro Shindo, Masashi Kondo, Kazuyoshi Imaizumi, Hiroaki Kume, Yoshinori Hasegawa, Kenzo Takagi, Hiroyuki Taniguchi
We conducted a phase II trial to evaluate the safety and efficacy of weekly paclitaxel in patients with resistant or relapsed non-small cell lung cancer (NSCLC) treated with docetaxel and carboplatin. Thirty-two NSCLC patients at a median age of 58.0 years (range 33–75) were enrolled. The Eastern Cooperative Oncology Group performance status scores (0/1/2) were 18/9/5, respectively. The majority of patients had adenocarcinoma (84%) and stage IV disease (81%). The response rate for the first-line...
Editors' Choice
Long-Term Posttransplant Bortezomib Boosts Outcome in Myeloma With del(17p13)
